1
|
Tizek L, Schuster B, Gebhardt C, Reich K, von Kiedrowski R, Biedermann T, Eyerich K, Zink A, Garzorz-Stark N. Molekulardiagnostik in der Dermatologie: Eine Online-Umfrage zur Untersuchung von Nutzung, Hürden und Anforderungen in Deutschland. J Dtsch Dermatol Ges 2022; 20:287-296. [PMID: 35304958 DOI: 10.1111/ddg.14659_g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Accepted: 09/20/2021] [Indexed: 11/28/2022]
Affiliation(s)
- Linda Tizek
- Technische Universität München, Medizinische Fakultät, Klinik und Poliklinik für Dermatologie und Allergologie, München, Deutschland
| | - Barbara Schuster
- Technische Universität München, Medizinische Fakultät, Klinik und Poliklinik für Dermatologie und Allergologie, München, Deutschland.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Schweden
| | - Christoffer Gebhardt
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Deutschland
| | - Kristian Reich
- Competenzzentrum Translationale Forschung bei entzündlichen Hauterkrankungen, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen, Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Deutschland
| | - Ralph von Kiedrowski
- Dermatologische Praxis und dermatologisches Studienzentrum (CMS3), Dr. Ralph von Kiedrowski, Selters/Westerwald, Deutschland
| | - Tilo Biedermann
- Technische Universität München, Medizinische Fakultät, Klinik und Poliklinik für Dermatologie und Allergologie, München, Deutschland
| | - Kilian Eyerich
- Technische Universität München, Medizinische Fakultät, Klinik und Poliklinik für Dermatologie und Allergologie, München, Deutschland.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Schweden
| | - Alexander Zink
- Technische Universität München, Medizinische Fakultät, Klinik und Poliklinik für Dermatologie und Allergologie, München, Deutschland.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Schweden
| | - Natalie Garzorz-Stark
- Technische Universität München, Medizinische Fakultät, Klinik und Poliklinik für Dermatologie und Allergologie, München, Deutschland.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Schweden
| |
Collapse
|
2
|
Tizek L, Schuster B, Gebhardt C, Reich K, von Kiedrowski R, Biedermann T, Eyerich K, Zink A, Garzorz-Stark N. Molecular diagnostics in dermatology: An online survey to study usage, obstacles and requirements in Germany. J Dtsch Dermatol Ges 2021; 20:287-295. [PMID: 34962069 DOI: 10.1111/ddg.14659] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Accepted: 09/20/2021] [Indexed: 12/16/2022]
Abstract
BACKGROUND AND OBJECTIVES Molecular diagnostics (MDx) increasingly gains importance in dermatology and its application is a prerequisite for personalized medicine. The goal of this cross-sectional study was to determine how MDx is implemented in dermatologists' offices in the three fields of oncology, inflammation and infectiology and which hurdles office-based dermatologists face in terms of MDx. METHODS Physician members of the Association of the German Dermatologists (Berufsverband der Deutschen Dermatologen e. V.; BVDD) were surveyed via an online questionnaire on MDx. RESULTS 39.6 % of the 192 participants reported using MDx. Of these, the vast majority used MDx for diagnosing infectious diseases (86.5 % and 44.3 % of users perform MDx for detection of funghi and sexually transmitted diseases, respectively). Only a small minority applied MDx to answer oncological or immunological questions. The major obstacles for non-users as compared to users were difficulties in implementation, lack of expertise as well as time, personnel, and technical availability. Reimbursement was a main issue in both groups. CONCLUSIONS Despite availability of specific therapies requiring precision medicine, MDx has not yet been broadly implemented in office-based dermatology. To advance MDx, more needs to be done in terms of continuous education, availability of reliable and valid tests, and reimbursability.
Collapse
Affiliation(s)
- Linda Tizek
- Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany
| | - Barbara Schuster
- Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Sweden
| | - Christoffer Gebhardt
- Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
| | - Kristian Reich
- Centre for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Ralph von Kiedrowski
- Dermatology Office and Dermatology Study Center (CMS3) Dr. Ralph von Kiedrowski, Selters/Westerwald, Germany
| | - Tilo Biedermann
- Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany
| | - Kilian Eyerich
- Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Sweden
| | - Alexander Zink
- Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Sweden
| | - Natalie Garzorz-Stark
- Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
3
|
Schacht V, Lehmann U, Reineke-Plaass T, Länger F, Auber B, Morlot S, Kreipe HH. [Possibilities and limitations of molecular pathology in dermatohistology]. Hautarzt 2018; 69:563-569. [PMID: 29876610 DOI: 10.1007/s00105-018-4206-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Malignant tumours, infections caused by microorganisms or genodermatoses are diagnosed with additional help of molecular pathology methods. Polymerase chain reaction (PCR), sequencing and in situ hybridisations play an important role. It remains to be seen if methods such as "liquid biopsies" or "single cell genomics" can be developed as routine diagnostics. High technical efforts, high costs and no possibility for resistency testing is accompanied by fast verification, high sensitivity and high specificity. Overall, molecular pathology results have to be combined with the clinical picture, histology or immunohistochemistry and culturing results to achieve a correct diagnosis for the patient.
Collapse
Affiliation(s)
- V Schacht
- Klinik für Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
| | - U Lehmann
- Institut für Pathologie, Medizinische Hochschule Hannover, Hannover, Deutschland
| | - T Reineke-Plaass
- Institut für Pathologie, Medizinische Hochschule Hannover, Hannover, Deutschland
| | - F Länger
- Institut für Pathologie, Medizinische Hochschule Hannover, Hannover, Deutschland
| | - B Auber
- Institut für Humangenetik, Medizinische Hochschule Hannover, Hannover, Deutschland
| | - S Morlot
- Institut für Humangenetik, Medizinische Hochschule Hannover, Hannover, Deutschland
| | - H-H Kreipe
- Institut für Pathologie, Medizinische Hochschule Hannover, Hannover, Deutschland
| |
Collapse
|